Christopher Ling, Mercer University College of Pharmacy
Asthma is a prevalent disorder that affects approximately 300 million people worldwide and is projected to increase to 400 million by 2025.  While most patients can be managed on current recommended therapies (e.g. long-acting and short-acting beta agonists [LABAs/ SABAs], inhaled glucocorticoids, long-acting and short-acting muscarinic antagonists), some patients remain uncontrolled.  Thymic stromal lymphopoietin (TSLP) is a cytokine produced in response to environmental and proinflammatory stimuli with the ability to promote B cell and dendritic cell activation.  Its expression is increased in patients with severe asthma and is suggested to be correlated with Th2 cytokine and chemokine expression. 
Tezepelumab is a human IgG2 monoclonal antibody that inhibits TSLP interactions with TSLP receptor complexes. One study showed that in mild, atopic asthmatic patients, tezepelumab inhibited both early and late asthmatic response and suppressed biomarkers of type 2 inflammation after inhaled allergen challenge.  To further explore the effectiveness of tezepelumab, the following study evaluated the effects of tezepelumab in patients with moderate-to-severe asthma who were uncontrolled with LABAs combined with medium-to-high doses of inhaled glucocorticoids.